Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP199 | DOI: 10.1530/endoabs.49.EP199

ECE2017 Eposter Presentations: Adrenal and Neuroendocrine Tumours Neuroendocrinology (9 abstracts)

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinico-pathological characteristics and disease outcome of 110 patients treated at single referral medical center

Shlomit Koren 1 , Karen Or 1 , Miri Steinschneider 1 , Esther Kummer 1 , Nirit Yarom 2, , Haim Shirin 3, , Ron Lavy 4 , Gratiana Gratiana 5, & Carlos Benbassat 1,

1Department of Endocrinology, Asaf Harofe Medical Center, Zeriffin, Israel; 2Department of Oncology, Asaf Harofe Medical Center, Zeriffin, Israel; 3Department of Gastroenterology, Asaf Harofe Medical Center, Zeriffin, Israel; 4Department of Surgery, Asaf Harofe Medical Center, Zeriffin, Israel; 5Department of Pathology, Asaf Harofe Medical Center, Zeriffin, Israel; 6Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Introduction: GEP-NETs incidence increased markedly over the past decades probably due to increased imaging. GEP-NETs are generally indolent but often have unpredictable biological behavior and aggressive clinical course.

Aims: To collect information regarding demographics, presentation, pathology characteristics, treatment and outcome of GEP-NETs.

Methods: Following approval of our institutional ethical board, pathology and clinical records of all GEP-NETs patients diagnosed and treated at our institution during 2005–2015 were reviewed.

Results: We identified 110 patients with GEP-NETs distributed by site as pancreatic 32 (F=45.1%, age 61.2±6.8), gastric 19 (F=50%, age 66.2±11), duodenum 9 (F=33.3%, age 66.3±12), small bowel 13 (F=25%, age 60±12), appendix 34 (F=55.8%, age 36±19) and colorectal 3. The pNETs presented with abdominal pain (45.1%) incidentally (25.8%) or syndromatic (21.8%); including two insulinomas, one gastrinoma and four MEN1 patients. Mean size was 31±23 mm and grading was G1 39.2, G2 42.8, G3 17.8%. Distant metastases (DM) were seen in five patients (M1=3). Surgery was performed in 61.3%, additional treatment given to 32.2% (re-op, somatostatin analogue, TKI, chemotherapy). The gNETs presented mostly during work-up for anemia or GI bleeding (70.6%). Mean size was 15 mm and the majority (82.3%) were GCT1 and there were no DM. The dNETs presented with anemia (43%), abdominal pain (43%) or incidentally. None was syndromatic. Mean size was 11.2 mm, 50% were G1, and 2 had DM at presentation. Surgery was performed in 33.3% patients. The sbNETs presented with bowel obstruction (27%), abdominal pain (36%) or incidentally. None were syndromatic. Only 15% were G1, 6 had DM (M1=5), and 77% had surgery. Excluding aNETs, the overall mortality at last visit was 23.7% (7.9% disease related) at mean follow-up of 34.5 months.

Conclusion: GEP-NETs are associated with significant morbidity and mortality. The primary site of the tumor has clinical implication for disease management.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.